Transgene Biotek’s oral insulin 'TrabOrlin' reports another excellent result

21 Jul 2012 Evaluate

Transgene Biotek’s patented oral insulin TrabOrlin has once again proven the efficacy and high bio-availability in yet another extensive randomized single blinded study conducted at a reputed CRO facility on a large number of animals. This data reconfirms the exciting results reported earlier from another study center. This is a significant milestone in the development of oral insulin by the company, which embarked on this project nearly 10 years ago overcoming several technology challenges.

This milestone not only accelerates project development towards the next stage but also provides an opportunity to seek strategic deals with pharma majors and other in-licensing partners. Besides, these exciting results of TrabOrlin’s coincide with the sale of DHA (approximately 5 tonne per year) from one customer alone and the company has already started delivering the consignments. The company is expecting to receive several other orders to follow in the coming days.

It is probably the only company in India that produces and supplies vegetable (Algal) sourced DHA in both oil and powder form. The above two progressive strides by the company are in addition to the other oncology and auto-immune projects advancing as per the schedules. Transgene Biotek is a biotechnology company. It is involved in the development of several cutting edge technologies.

Transgene Biotek Share Price

7.07 0.14 (2.02%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7036.65
Max Healthcare Inst 1006.75
Narayana Hrudayalay 1249.35
Aster DM Healthcare 444.55
Global Health 1115.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.